| Project/Area Number |
11670774
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | YOKOHAMA CITY UNIVERSITY |
|---|
Principal Investigator |
AIHARA Yukoh YOKOHAMA CITY UNIV.MEDICAL CENTER, ASSOCIATE PROFESSOR, 医学部・附属病院, 助教授 (50211686)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NEZU Atsuo YOKOHAMA CITY UNIV.MEDICAL CENTER, ASSISTANT PROFESSOR, 医学部・附属病院, 講師 (10237810)
YOKOTA Shumpei YOKOHAMA CITY UNIV.SCH.OF MED., PROFESSOR, 医学部, 教授 (10158363)
大槻 則行 横浜市立大学, 医学部・附属病院, 助手 (00264622)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2000: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1999: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Keywords | ACUTE ENCEPHALOPATHY IN CHILDREN / THERAPY / HYPOTHERMIA / 小児 |
|---|
| Research Abstract |
ACUTE ENCEPHALOPATHY IS ONE OF SEVERE DISORDERS IN CHILDHOOD.ALTHOUGH, IT'S PATHOPHYSIOLOGY REMAINS UNKNOWN, IT IS NOW KNOWN THAT ONE OF RELATED FACTORS IS INFLUENZA VIRUS INFECTION.THE INFLUENZA INFECTION MIGHT INDUCE THE FAILURE OF BLOOD-BRAIN BARRIER AND THE ABNORMAL PRODUCTION OF SEVERAL CYTOKINES, FOLLOWED BY THE MASSIVE DEATH OF NEURONS.THEREFORE, THE STRATEGY TO TREAT THE DISEASE IS TO PREVENT THE CASCADE OF THE EVENTS.IN ADDITION, WE REPORTED THAT THERE WAS A LIMITED EFFICACY IN THE DISEASE WITH THE CONVENTIONAL THERAPIES.THEREFORE, WE TRY TO ESTABLISH A NOVEL THERAPY INCLUDING MILD HYPOTHERMIA AND METHYLPREDNISOLONE PULSE THERAPY TO IMPROVE THE OUTCOME OF THE PATIENTS WITH THE DISEASE.
BEFORE STARTING THE NEW THERAPY, WE ANALYZED THE PRECISE DATA OF 35 PATIENTS WITH ACUTE ENCEPHALOPATHY UNDER THE CONVENTIONAL THERAPY.THE OUTCOME WAS BAD.THAT IS, 10 PATIENTS WERE DEAD.ONE THIRD HAD SEVERE DISABILITY IN DAILY LIFE.ONE THIRD HAD MILD DISABILITIES.
WE ESTABLISHED A NOVEL THERAPY INCLUDING MILD HYPOTHERMIA AND METHYLPREDNISOLONE COMBINATION AGAINST ACUTE ENCEPHALOPATHY AND/OR ENCEPHALITIS.SO FAR WE APPLIED THIS THERAPY TO 10 PATIENTS.IT SEEMS THAT THE OUTCOMES OF THE PATIENTS WITH THIS THERAPY BECOME BETTER THAN THOSE WITH CONVENTIONAL THERAPY.IT IS TOO EARLY TO CONCLUDE THE EFFICACY OF THIS NEW THERAPY.HOWEVER, WE BELIEVE THAT THIS NOVEL THERAPY IS PROMISING.NOW, TO ESTABLISH THE THERAPY WE HAVE TO DETERMINE A CRITERIA OF THE PATIENTS TO APPLY THE THERAPY AS WELL AS TO INCREASE THE NUMBER OF THE PATIENTS WITH THE THERAPY.
|
